Cargando…
Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial
BACKGROUND: The RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial demonstrated that higher-risk patients with atrial fibrillation had lower rates of stroke or systemic embolism and a similar rate of major bleeding, on average, when treated with dabigatran 150mg compared to war...
Autores principales: | Reinhardt, Samuel W., Desai, Nihar R., Tang, Yuanyuan, Jones, Philip G., Ader, Jeremy, Spertus, John A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376053/ https://www.ncbi.nlm.nih.gov/pubmed/34411158 http://dx.doi.org/10.1371/journal.pone.0256338 |
Ejemplares similares
-
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study
por: Verdecchia, Paolo, et al.
Publicado: (2018) -
Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014) -
Efficacy and safety of dabigatran versus warfarin from the RE-LY trial
por: Avezum, Alvaro, et al.
Publicado: (2018) -
Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study
por: Calkins, Hugh, et al.
Publicado: (2019) -
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban
por: Winkle, Roger A., et al.
Publicado: (2014)